Nephrol Dial Transplant. 2026 Oct 12:gfag233. doi: 10.1093/ndt/gfag233. Online ahead of print.
ABSTRACT
For several decades, there was no clinical-trial evidence to demonstrate that intensive blood pressure (BP)-lowering is a therapeutic strategy that prolongs survival and reduces the cardiorenal risk of patients with chronic kidney disease (CKD). In 2015, the landscape changed after the publication of the SPRINT (Systolic Blood Pressure Intervention Trial). Compared with a standard (<140 mmHg) systolic BP (SBP), an impressive cardiovascular and survival benefit was observed with an intensive (<120 mmHg) SBP target in non-diabetic patients with hypertension and high cardiovascular risk provoking premature termination of SPRINT. In 2017, a prespecified subgroup analysis of SPRINT showed that the benefit of intensive BP-lowering was similar in patients with or without CKD. As expected, this landmark trial has substantially influenced the BP target recommendations from the guidelines released thereafter. In 2021, the KDIGO guideline made a breakthrough with the adoption of the intensive SBP target of SPRINT for the management of hypertension in CKD. However, other major medical panels, like ESC, ERA, NICE, ACC and AHA have been reluctant to follow the same approach and the optimal BP goal in CKD continues to be debated. In this article, we provide evidence defending and opposing the position that the SBP target in CKD should be <120 mmHg. We conclude with a consensus and suggestions for the successful implementation of this intensive SBP target in daily clinical practice.
PMID:42861937 | DOI:10.1093/ndt/gfag233